Suven Life Sciences has announced positive topline results from its Phase-2b clinical proof-of-concept trial of Ropanicant for the treatment of Major Depressive Disorder (MDD). The trial demonstrated that twice-daily oral administration of Ropanicant 45 mg resulted in a clinically meaningful improvement in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score at Week 6, the primary endpoint, compared to placebo. The company is now planning a global Phase-3 registrational study for the drug candidate.

Phase-2b Clinical Trial Efficacy

The randomized, double-blind, placebo-controlled trial enrolled 214 patients across 35 sites in the United States for a treatment duration of six weeks. The maximum likelihood (ML) estimated mean difference from baseline versus placebo was -3.572 in the Full Analysis Set (p = 0.038), -3.570 in the modified Full Analysis Set (p = 0.038), and -4.067 in the Per-Protocol Set (p = 0.023). Existing clinical evidence identifies a difference of approximately 2 points in MADRS total score versus placebo as clinically meaningful.

Safety and Secondary Endpoints

Ropanicant was generally well tolerated, with the majority of treatment-emergent adverse events reported as mild to moderate. No withdrawal symptoms were observed after discontinuation, and there was no evidence of dissociation. Assessment of clinical laboratory parameters, electrocardiogram (ECG) parameters, and vital signs revealed no clinically meaningful changes. Evidence of treatment benefit was observed across secondary endpoints, including the Clinical Global Impression–Severity of Illness (CGI-S; p = 0.094) and the Sheehan Disability Scale (SDS; p = 0.039).

Strategic Outlook

Suven Life Sciences stated that a priority patent application has already been filed, with an International Application claiming priority to be filed shortly. Mr. Venkat Jasti, Chairman and Managing Director, highlighted the potential of Ropanicant as a differentiated treatment option to meet significant unmet medical needs. Mr. Ramakrishna Nirogi, President and CSO, noted that the company looks forward to engaging with regulatory authorities worldwide to discuss Phase-3 clinical development plans.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE495B01038/55b8bd5d29864b5b.pdf

Suven Life Sciences announced the successful completion of the Phase-1 first-in-human (FIH) clinical study for SUVN-I6107, a novel muscarinic M1 positive allosteric modulator (M1-PAM), on June 16, 2026. The study results demonstrated a favorable safety and tolerability profile with no dose-limiting toxicities, alongside robust pharmacodynamic activity indicating central nervous system (CNS) engagement. These findings support the advancement of SUVN-I6107 into Phase-2 clinical development, marking a significant milestone in the company's pipeline for treating CNS disorders.

The randomized, double-blind, placebo-controlled study (NCT06705088) was conducted in two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD). The SAD segment enrolled 40 participants across five cohorts, assessing food effects and sex-related differences. The MAD segment enrolled 24 participants across three cohorts, with daily dosing for 14 consecutive days. Translational biomarkers were incorporated to assess CNS activity and confirm the compound's mechanism of action.

Key Study Findings

SUVN-I6107 exhibited predictable, dose-proportional pharmacokinetics, achieving projected therapeutic exposures in plasma and at the target site. The median time to peak plasma concentration was approximately 2–6 hours, with a mean elimination half-life of 7 to 11 hours. Pharmacokinetic assessments showed no clinically meaningful differences between male and female participants, and food intake had no clinically relevant impact on the drug's profile. Pharmacodynamic biomarker assessments indicated increased alertness and enhanced information processing.

Safety data indicated that no predefined dose-escalation stopping criteria were met, and no treatment-related adverse events led to discontinuation. No serious adverse events or deaths were reported, with all observed events being mild to moderate and resolving prior to study completion.

Management Commentary

Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, highlighted the significance of the milestone. "The completion of the Phase-1 study for SUVN-I6107 represents an important development milestone for the M1-PAM program and further expands our clinical-stage pipeline in neuroscience," he said. Mr. Ramakrishna Nirogi, President and Chief Scientific Officer, added that the data provides evidence of CNS activity and supports the transition to Phase-2 evaluation.

SUVN-I6107 is the fifth internally discovered candidate to enter clinical development for Suven Life Sciences. The company retains intellectual property rights for the asset in all major markets.